Site icon pharmaceutical daily

Worldwide Organ Transplant Immunosuppressant Drugs Industry to 2028 – Featuring Novartis, Mylan Laboratories and Leo Pharma Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Organ Transplant Immunosuppressant Drugs Market, by Drugs Class, by Therapeutic Organ Transplant Type, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026” report has been added to ResearchAndMarkets.com’s offering.

After a successful organ transplant, you may have to take immunosuppressant drugs. These drugs help your immune system from attacking (rejecting) the new organ from which it has been transplanted.

In general, they should be taken for your lifetime, or until the treatments are complete. Orally, or injected into a vein, these drugs work by stopping your body’s immune cells from further attacking your transplanted organ. They also control your allergic reactions to the transplanted organ and reduce inflammation around the transplanted tissues.

Market Dynamics:

Approval and launch of new drugs is expected to propel growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, in July 2021, Kadmon Holdings, Inc. received the U.S. Food and Drug Administration approval for REZUROCK (belumosudil) for the treatment of adult and pediatric patients with chronic graft-versus-host disease.

Negative outcomes in clinical trials is expected to hinder growth of the global organ transplant immunosuppressant drugs market. For instance, in September 2021, Novartis AG announced to halt a mid-stage clinical trial of drug intended to prevent organ rejection after an early look at data in kidney transplant patients showed the experimental treatment was less effective compared to the standard of care therapy.

The market is witnessing several M&A activities. For instance, in September 2021, Sanofi announced to acquire Kadmon Holdings, a U.S.-based biopharmaceutical company.

Key features of the study:

Company Profiles

Key Topics Covered:

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Organ Transplant Immunosuppressant Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

5. Global Organ Transplant Immunosuppressant Drugs Market, By Drug Type, 2017 – 2028 (US$ Mn)

6. Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type, 2017 – 2028 (US$ Mn)

7. Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel, 2017 – 2028 (US$ Mn)

8. Global Organ Transplant Immunosuppressant Drugs Market, By Region, 2017 – 2028 (US$ Mn)

9. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/g0fmmg

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version